These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1243 related articles for article (PubMed ID: 23635324)

  • 1. Immunity, atherosclerosis and cardiovascular disease.
    Frostegård J
    BMC Med; 2013 May; 11():117. PubMed ID: 23635324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune mechanisms in atherosclerosis, especially in diabetes type 2.
    Frostegård J
    Front Endocrinol (Lausanne); 2013 Oct; 4():162. PubMed ID: 24194733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease.
    Frostegård J
    Clin Immunol; 2010 Jan; 134(1):47-54. PubMed ID: 19748321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural antibodies against phosphorylcholine in cardiovascular disease.
    de Faire U; Frostegård J
    Ann N Y Acad Sci; 2009 Sep; 1173():292-300. PubMed ID: 19758165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation.
    Frostegård J
    Expert Rev Clin Immunol; 2022 May; 18(5):525-532. PubMed ID: 35471137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmunity, oxidized LDL and cardiovascular disease.
    Frostegård J
    Autoimmun Rev; 2002 Aug; 1(4):233-7. PubMed ID: 12849001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
    Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
    Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses.
    Rhoads JP; Major AS
    Crit Rev Immunol; 2018; 38(4):333-342. PubMed ID: 30806246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophages and dendritic cells: the usual suspects in atherogenesis.
    Kassiteridi C; Monaco C
    Curr Drug Targets; 2015; 16(4):373-82. PubMed ID: 25808566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLE, atherosclerosis and cardiovascular disease.
    Frostegård J
    J Intern Med; 2005 Jun; 257(6):485-95. PubMed ID: 15910552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy.
    McLaren JE; Michael DR; Ashlin TG; Ramji DP
    Prog Lipid Res; 2011 Oct; 50(4):331-47. PubMed ID: 21601592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylcholine-targeting immunization reduces atherosclerosis.
    Caligiuri G; Khallou-Laschet J; Vandaele M; Gaston AT; Delignat S; Mandet C; Kohler HV; Kaveri SV; Nicoletti A
    J Am Coll Cardiol; 2007 Aug; 50(6):540-6. PubMed ID: 17678738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting inflammation in cardiovascular diseases. still a neglected field?
    Gómez-Guerrero C; Mallavia B; Egido J
    Cardiovasc Ther; 2012 Aug; 30(4):e189-97. PubMed ID: 21884009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation and immune system interactions in atherosclerosis.
    Legein B; Temmerman L; Biessen EA; Lutgens E
    Cell Mol Life Sci; 2013 Oct; 70(20):3847-69. PubMed ID: 23430000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors.
    Sun J; Lundström SL; Zhang B; Zubarev RA; Steuer J; Gillgren P; Rahman M; Ajeganova S; Liu A; Frostegård J
    Atherosclerosis; 2018 Jan; 268():36-48. PubMed ID: 29175653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
    Muhammad K; Ayoub MA; Iratni R
    Curr Pharm Des; 2021; 27(18):2141-2150. PubMed ID: 33461451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation and atherosclerosis.
    Hansson GK; Robertson AK; Söderberg-Nauclér C
    Annu Rev Pathol; 2006; 1():297-329. PubMed ID: 18039117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease.
    Maranhão RC; Leite AC
    Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.
    Stoll G; Bendszus M
    Stroke; 2006 Jul; 37(7):1923-32. PubMed ID: 16741184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against Phosphorylcholine-Implications for Chronic Inflammatory Diseases.
    Frostegård J
    Metabolites; 2023 Jun; 13(6):. PubMed ID: 37367878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.